https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

ISTH 2025: Abelacimab Demonstrates Low Periprocedural Bleeding Rates in Phase 2 Trial

ISTH 2025: Abelacimab Demonstrates Low Periprocedural Bleeding Rates in Phase 2 Trial

Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.

administrator

Related Articles